IFT57

Across TCGA pan-cancer cohorts, IFT57 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IFT57 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher IFT57 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IFT57 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where IFT57 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.683	0.923	<.001	27	view →
PDAC	DFS	Tertile	III,IV	0.918	0.258	.006	19	view →
CCRCC	DFS	Tertile	III,IV	0.310	0.790	.005	17	view →
LSCC	DFS	Median	II,III,IV	0.861	0.974	.005	15	view →
LUAD	OS	Quartile	All	0.899	0.424	.001	10	view →
HNSC	OS	Tertile	III,IV	0.422	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IFT57–GBM (OS)

Open the GBM breakdown →